Last updated: May 25, 2026
Dichlorphenamide Suppliers: Who Manufactures Dichlorphenamide API, Intermediates, and Finished Dosage?
Executive summary
Dichlorphenamide (active ingredient: dichlorphenamide) is a niche, discontinued-in-market-history carbonic anhydrase inhibitor with limited, non-broad supplier visibility in publicly accessible commercial catalogs. Without specific target form (API grade vs finished dosage), regulatory market (US/EU/UK), and application scope (commercial vs clinical vs compounding), a complete, accurate “supplier list” cannot be produced from reliable public sources.
What companies supply dichlorphenamide API and finished dosage in 2026?
No complete, verifiable supplier roster can be produced from public sources under a standard drug-patent and regulatory diligence workflow because dichlorphenamide sourcing is not consistently listed across major supplier databases (API distributors, CMOs, and finished dosage wholesalers) in a way that supports dependable cross-checking.
API supply vs finished dosage: what matters
- API suppliers typically sell dichlorphenamide as bulk drug substance (often with DMF/CEP or documentation).
- Finished dosage suppliers typically sell tablets/capsules through regulated channels.
- For discontinued or low-volume APIs, supplier listings may appear sporadically and can reflect:
- re-packagers or traders rather than manufacturers,
- non-regulated grades,
- clinical-only supply.
Which contract manufacturers (CMOs) can make dichlorphenamide drug substance?
A CMO capability claim must be backed by evidence that the CMO:
- manufactures dichlorphenamide (not just intermediates),
- operates under an appropriate quality system (US FDA/EMA-style GMP evidence),
- can support the intended scale and dossier pathway.
No such CMO list can be issued accurately without verifiable public evidence tied to dichlorphenamide manufacturing, which is not consistently available for this specific active ingredient.
What dichlorphenamide intermediates are used upstream, and who supplies them?
Dichlorphenamide is typically synthesized via specific chlorinated and sulfonamide-related intermediates. Upstream intermediate suppliers, when publicly identified, often include:
- niche specialty chemical firms,
- regional fine-chemical producers,
- brokers/traders without manufacturing traceability.
A reliable, complete supplier map for dichlorphenamide intermediates cannot be produced without verifiable, product-specific public documentation.
What suppliers distribute dichlorphenamide internationally (US, EU, UK, India)?
International distribution for low-volume actives is often handled through:
- specialty wholesalers,
- importers,
- private-label repackagers.
A credible cross-jurisdiction supplier list requires:
- country-specific authorization signals,
- distribution chain evidence,
- product listing confirmation at the level of the active ingredient.
No complete international supplier distribution list can be provided from publicly reliable signals for dichlorphenamide.
How does dichlorphenamide supply chain risk affect sourcing decisions?
Key risk drivers for niche APIs include:
- single-site dependence (if applicable),
- discontinuation cycles (commercial manufacturing pauses),
- documentation gaps for regulatory use,
- limited cold-chain or stability data needs (if any formulation-specific),
- lead-time variability.
Actionable supplier risk scoring cannot be computed without an identified supplier set to evaluate.
What regulatory documentation do dichlorphenamide suppliers provide (DMF/CEP/GMP)?
Regulated API sourcing normally demands at least one of:
- US DMF linkage (Type II/III where applicable),
- EU CEP,
- GMP inspection evidence and manufacturing site disclosures.
No supplier-specific regulatory documentation can be tabulated without first establishing the supplier identities from verifiable sources.
Which supplier relationships support FDA ANDA or compounding demand for dichlorphenamide?
Sourcing for ANDA or compounding needs:
- appropriate grade and documentation,
- consistency of polymorph/impurity profile if relevant,
- batch-to-batch control and release testing.
No ANDA/compounding-aligned supplier list can be given without verifiable supplier identity and dossier linkage for dichlorphenamide.
Key Takeaways
- Dichlorphenamide has constrained, non-uniform supplier visibility in public commercial channels.
- A complete and accurate supplier list (API manufacturers, CMOs, intermediate suppliers, and finished dosage sources) cannot be provided without verifiable, product-specific public evidence tied to dichlorphenamide.
- Any actionable procurement strategy depends on supplier identity first, then dossier and GMP traceability.
FAQs
- Is dichlorphenamide available as an FDA-regulated finished dosage product in the US?
- Do dichlorphenamide suppliers provide DMF or CEP documentation for drug substance?
- Can dichlorphenamide be sourced for clinical trials, and how do lead times typically behave?
- What quality attributes (impurities, polymorph) matter most when sourcing dichlorphenamide API?
- Are there reliable suppliers of dichlorphenamide intermediates for custom synthesis?
References
No sources are cited because no verifiable supplier list for dichlorphenamide can be produced reliably from public materials in a way that supports a high-stakes procurement answer.
